Phase II LCMC3 Study of Neoadjuvant Atezolizumab Met Primary Endpoint with a Major Pathological Response Rate of 20% in Resectable Stage IB–IIIB NSCLC
Results of the largest study of preoperative immune checkpoint inhibitor monotherapy in patients with early-stage non-small cell lung cancer to date